Search

Your search keyword '"Varaldo, Riccardo"' showing total 338 results

Search Constraints

Start Over You searched for: Author "Varaldo, Riccardo" Remove constraint Author: "Varaldo, Riccardo"
338 results on '"Varaldo, Riccardo"'

Search Results

2. The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation

7. Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up

8. Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up

9. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography

11. Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide

12. Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor

13. An aggressive form of MOGAD treated with aHSCT: A case report

14. An aggressive form of MOGAD treated with aHSCT: A case report.

17. Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)

18. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation

19. Introduzione

20. Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors

24. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated with Expansion and Maturation of NK Cells

28. Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

30. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

31. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

35. Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality

36. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

37. Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

38. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin’s lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience

39. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

40. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

41. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis

42. OS-124-YI - Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)

44. Human capital, innovation and competitiveness in Italian industry

46. Second haploidentical stem cell transplantation for primary graft failure

47. Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

49. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab

50. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients

Catalog

Books, media, physical & digital resources